What is HC Wainwright’s Estimate for PVLA FY2027 Earnings?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for Palvella Therapeutics in a research report issued on Tuesday, February 24th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($3.43) per share for the year, up from their previous estimate of ($3.65). HC Wainwright has a “Buy” rating and a $255.00 price target on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2028 earnings at ($1.84) EPS, FY2029 earnings at $2.19 EPS and FY2030 earnings at $11.56 EPS.

A number of other research firms also recently commented on PVLA. Oppenheimer restated an “outperform” rating and set a $200.00 price objective on shares of Palvella Therapeutics in a report on Monday, December 15th. TD Cowen reiterated a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. Mizuho boosted their target price on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research report on Wednesday. Canaccord Genuity Group boosted their target price on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Finally, Raymond James Financial restated a “strong-buy” rating and set a $193.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $176.44.

Palvella Therapeutics Price Performance

NASDAQ PVLA opened at $135.02 on Thursday. Palvella Therapeutics has a 12 month low of $18.23 and a 12 month high of $151.18. The company has a 50-day moving average of $94.53 and a 200-day moving average of $79.99. The company has a market cap of $1.60 billion, a P/E ratio of -51.34 and a beta of -0.16.

Insider Activity

In other news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 20.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Palvella Therapeutics

Institutional investors have recently bought and sold shares of the business. Group One Trading LLC lifted its position in Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after buying an additional 200 shares in the last quarter. Archer Investment Corp acquired a new stake in Palvella Therapeutics in the 3rd quarter valued at approximately $28,000. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics during the 3rd quarter valued at $36,000. China Universal Asset Management Co. Ltd. bought a new position in Palvella Therapeutics during the fourth quarter valued at about $167,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in Palvella Therapeutics in the second quarter worth $37,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics News Summary

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target to $255 and materially boosted multi‑year EPS forecasts, reiterating a Buy rating — a strong analyst endorsement that can support higher valuation expectations. HC Wainwright Price Target/Upgrade
• Positive Sentiment: Chardan Capital also lifted its price target to $210, adding to a cluster of bullish analyst views and a high median street target (~$200) that can underpin demand for the stock. Chardan Price Target
• Positive Sentiment: The company successfully priced an upsized public offering of 1.6M shares at $125 per share (with a 30‑day option for an additional 240k shares), expected to generate approx. $200M in gross proceeds to fund development of QTORIN programs — a meaningful cash runway for a clinical‑stage biotech. Offering Pricing (GlobeNewswire)
• Neutral Sentiment: Some reports note the stock hit a multi‑year high in intraday trade following the upsized offering — showing demand and market interest, but not necessarily a durable trend. Investing.com Article
• Negative Sentiment: All shares in the offering are being sold by Palvella (company‑issued), which will dilute existing holders and can pressure the stock as the new supply hits the market. The offering’s dilutive effect likely contributed to downward pressure despite the cash infusion. Quiver Quant Offering Summary
• Negative Sentiment: Short interest rose ~22% in February to ~1.67M shares (≈17.8% of float), increasing potential selling pressure and volatility (days‑to‑cover ~5.5). Combined with recent insider selling, these are headwinds for the share price. (internal data)

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.